CN Patent

CN121622680A — 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Assigned to Karuna Therapeutics Inc · Expires 2026-03-10 · 0y expired

What this patent protects

本公开提供用于治疗由毒蕈碱受体激活所改善的障碍的组合物和方法。具体而言，本公开涉及包含呫诺美林或其盐、曲司氯胺盐和3‑[(4‑己氧基)‑1,2,5‑噻二唑‑3‑基]‑5‑羟基‑1‑甲基吡啶‑1‑鎓的药物组合物。本公开还涉及所述组合物作为药物的用途，用于治疗人或动物受试者中由毒蕈碱受体激活所改善的障碍。

USPTO Abstract

本公开提供用于治疗由毒蕈碱受体激活所改善的障碍的组合物和方法。具体而言，本公开涉及包含呫诺美林或其盐、曲司氯胺盐和3‑[(4‑己氧基)‑1,2,5‑噻二唑‑3‑基]‑5‑羟基‑1‑甲基吡啶‑1‑鎓的药物组合物。本公开还涉及所述组合物作为药物的用途，用于治疗人或动物受试者中由毒蕈碱受体激活所改善的障碍。

Drugs covered by this patent

Patent Metadata

Patent number: CN121622680A
Jurisdiction: CN
Classification: —
Expires: 2026-03-10
Drug substance claim: No
Drug product claim: No
Assignee: Karuna Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.